Acorda Sets Ampyra Price Above Estimates, Reaps Benefit Of Clean Labeling

Highlighting the upside of receiving clean labeling from FDA, Acorda set the price for its multiple sclerosis drug Ampyra higher than the company had originally projected - at nearly $13,000/year per patient